Hydroxychloroquine in Cystic Fibrosis
Hydroxychloroquine in Cystic Fibrosis
Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis
 before and after a 4 week course of oral hydroxychloroquine.
Open label study of effect of hydroxychloroquine on inflammation, bacterial burden and
 exhaled breath condensate pH in patients with cystic fibrosis. Patients with cystic fibrosis,
 16 years or older and with pulmonary function tests with an FEV1 greater than 40% predicted
 will be eligible for enrollment. Enrolled subjects will undergo collection of exhaled breath
 condensate and sputum induction and collection following nebulized hypertonic saline, before
 and following a 4 week course of oral hydroxychloroquine at 200 mg a day. Inflammatory
 mediators, neutrophil counts, and bacterial density in sputum and exhaled breath condensate
 pH will be measure at entry and at the end of 4 weeks of oral drug. There will be no placebo
 group.
Inclusion Criteria:

 1. Male or female between 16 years and 65 years of age.

 2. Confirmed diagnosis of CF based on the following criteria:

 i. positive sweat chloride 60 mEq/liter (by pilocarpine iontophoresis) and/or ii. a
 genotype with two identifiable mutations consistent with CF, and iii. accompanied by
 one or more clinical features consistent with the CF phenotype

 3. FEV1 50% predicted value (subjects 16- <18 years of age) or 40% predicted value
 (subjects 18 years of age)

 4. Clinically stable with no evidence of acute upper or lower respiratory tract infection
 or current pulmonary exacerbation within the 14 days prior to Visit 1 (Day 0)

 5. Ability to reproducibly perform spirometry and peak flow measurements

 6. Ability to understand and sign a written informed consent or assent and comply with
 the requirements of the study

 Exclusion Criteria:

 1. Use of an investigational agent within the 4-week period prior to Visit 1

 2. Chronic daily use of ibuprofen or other NSAIDs, or systemic corticosteroids, or any
 oral diabetic or hypoglycemic agent within the 4 weeks prior to Visit 1 or acute usage
 within 72 hours prior to Visit 1

 3. History of hypersensitivity to beta-agonists

 4. History of hypersensitivity to hydroxychloroquine or chloroquine

 5. Oxygen saturation < 92% on room air at Visit 1

 6. Pregnant, breastfeeding, or unwilling to practice birth control during participation
 in the study

 7. History of hemoptysis 30 cc per episode during the 30 days prior to Visit 1

 8. Significant history of hepatic, cardiovascular, renal, neurological, hematologic, or
 peptic ulcer disease